Quantum BioPharma

Quantum BioPharma Innovating in Neurodegenerative Disease & Alcohol Health. Creators of unbuzzd™️ & Lucid-MS. Strong Execution. Diversified Treasury. NASDAQ symbol $QNTM

08/05/2025

Quantum BioPharma announces positive results from the Clinical Study Report (CSR) of its Phase 1 Multiple Ascending Dose (MAD) clinical trial evaluating Lucid-21-302 (Lucid-MS), an investigational therapy for Multiple Sclerosis (MS).

These encouraging findings represent a significant advancement in our efforts to address demyelination in neurodegenerative disorders, specifically for MS.

📄 Read the full news release:

🔗 https://www.globenewswire.com/news-release/2025/08/05/3127241/0/en/Quantum-Biopharma-Announces-Positive-Results-of-the-Clinical-Study-Report-CSR-for-the-Phase-1-Multiple-Ascending-Dose-MAD-Clinical-Trial-of-Experimental-Multiple-Sclerosis-Drug-Luc.html

$QNTM

07/30/2025

Quantum BioPharma | Tackling a Global Challenge
Approximately 2.9 million people worldwide are living with Multiple Sclerosis (MS) — a chronic neurodegenerative disease marked by demyelination of the central nervous system.

Source of Map : https://atlasofms.org/map/global/epidemiology/number-of-people-with-ms

At Quantum BioPharma, we are committed to advancing science that targets the underlying biology of MS as a neurodegenerative approach.

Our mission is clear: to confront demyelination head-on.

📈 NASDAQ: $QNTM
🌐 www.quantumbiopharma.com

07/28/2025

Quantum BioPharma is advancing research in Multiple Sclerosis with Lucid-MS, a novel therapeutic candidate targeting neurodegeneration.

Advancing Science, Saving Lives.

Learn more: www.quantumbiopharma.com

$QNTM

07/21/2025

🧠 Disrupted neural communication is a key challenge in Multiple Sclerosis.

Lucid-MS, Quantum BioPharma’s investigational therapy, is designed to target demyelination—a core driver of this disruption.

We’re advancing science with a clear focus: restoring the pathways that matter.

Learn More --> https://www.quantumbiopharma.com/lucid-ms

📊 $QNTM |

07/11/2025

🔬 Advancing the Science of Demyelination.

Dedicated to Addressing the Complexities of Neurodegenerative Disease.

Quantum BioPharma Operates with Scientific Integrity at Every Step.

Learn more at:
🌐 www.quantumbiopharma.com

$QNTM

07/08/2025

Quantum BioPharma has submitted its patented MS drug candidate, Lucid-21-302 (Lucid-MS), to the UK’s Innovative Licensing and Access Pathway (ILAP) fast-track program.

Lucid-MS is a first-in-class treatment targeting demyelination in Multiple Sclerosis.

The ILAP submission marks a key step in accelerating regulatory review, clinical development, and patient access in the UK.

https://www.globenewswire.com/news-release/2025/07/08/3111671/0/en/Quantum-BioPharma-Submits-its-Candidate-Breakthrough-Patented-Drug-for-Multiple-Sclerosis-for-Fast-Track-Program-in-the-United-Kingdom.html

$QNTM

07/07/2025

NEWS RECAP JUNE 17th 2025

Quantum BioPharma ($QNTM) and Massachusetts General Hospital (MGH) have officially scanned the first person with Multiple Sclerosis using a next-generation PET-MR imaging tracer—[¹⁸F]3F4AP, Using latest tech GE Signa PET-MR.

This groundbreaking joint study is designed to evaluate a novel PET biomarker that detects myelin damage in the brain and spinal cord with unprecedented clarity. The goal? To transform how MS drug candidates are measured for remyelination and neuroprotection—ushering in a new era of precision imaging in MS research.

🧠 Precision PET imaging
🤝 Leading collaboration with MGH
🔬 Pioneering biomarker science
💊 Supporting future MS therapies

Read the full story:
https://www.globenewswire.com/news-release/2025/06/17/3100574/0/en/Quantum-BioPharma-Announces-First-Person-with-Multiple-Sclerosis-MS-Scanned-in-Joint-Study-with-Massachusetts-General-Hospital.html

$QNTM

Address

Toronto, ON

Telephone

+14168548884

Website

Alerts

Be the first to know and let us send you an email when Quantum BioPharma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category